Concurrent use of ketamine and monoamine oxidase inhibitors in the treatment of depression: A letter to the editor

Gen Hosp Psychiatry. 2018 Sep-Oct:54:62-64. doi: 10.1016/j.genhosppsych.2018.05.007. Epub 2018 May 22.

Authors

R B Katz¹, M Toprak², S T Wilkinson², G Sanacora², R Ostroff²

Affiliations

¹ Yale Department of Psychiatry, Yale School of Medicine, 184 Liberty Street, New Haven, CT, USA. Electronic address: [email protected].
² Yale Department of Psychiatry, Yale School of Medicine, 184 Liberty Street, New Haven, CT, USA.

No abstract available

Keywords: Depression; Ketamine; Monoamine oxidase inhibitor; Safety; Treatment-refractory.

Publication types

Letter
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

MeSH terms

Adult
Aged
Antidepressive Agents / administration & dosage
Antidepressive Agents / adverse effects
Antidepressive Agents / pharmacology*
Depressive Disorder, Major / drug therapy*
Drug Therapy, Combination / adverse effects
Female
Humans
Ketamine / administration & dosage
Ketamine / adverse effects
Ketamine / pharmacology*
Middle Aged
Monoamine Oxidase Inhibitors / adverse effects
Monoamine Oxidase Inhibitors / pharmacology*

Substances

Antidepressive Agents
Monoamine Oxidase Inhibitors
Ketamine

Grants and funding